Status:
COMPLETED
Pharmacokinetics of Teicoplanin in Intensive Care and Haematology Patients
Lead Sponsor:
Radboud University Medical Center
Conditions:
Bacterial Infections
Eligibility:
All Genders
18+ years
Brief Summary
Characterize teicoplanin PK in critically ill patients with a specific focus on alterations of exposure due to variability in renal function. In a prospective, observational, open-label study the inv...
Detailed Description
Bacterial infection with coagulase-negative staphylococci (CNS) or methicillin resistant and sensitive staphylococcus aureus(MRSA/MSSA) indicates poor prognosis and increased mortality in critically i...
Eligibility Criteria
Inclusion
- The patient is admitted to the ICU of the haematology department
- The patient is at least 18 years of age on the day of inclusion
- Is managed with a central venous catheter or arterial line
- Is treated with teicoplanin as a part of standard care
Exclusion
- Has previously participated in this study
- Patient is admitted to the haematology department and receives any form of RRT other than continuous venovenous hemofiltration (CVVH).
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04096092
Start Date
January 15 2020
End Date
December 1 2022
Last Update
January 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands